Cutaneous leishmaniasis: progress towards a vaccine

References

• Zijlstra EE, Musa AM, Khalil EA, el-Hassan IM, el-Hassan AM. Post-kalaazar dermal leishmaniasis. Lancet Infect. Dis.3(2), 87–98 (2003).
   PubMed Web of Science ®Google Scholar
• Desjeux P, Alvar J. Leishmania /HIV co-infections: epidemiology in Europe. Ann. Trop. Med. Parasitol.97(Suppl. 1), 3–15 (2003).
   PubMed Web of Science ®Google Scholar
• Cruz I, Morales MA, Noguer I, Rodriguez A, Alvar J. Leishmania in discarded syringes from intravenous drug users. Lancet359(9312), 1124–1125 (2002).
   PubMed Web of Science ®Google Scholar
• Dye C. The logic of visceral leishmaniasis control. Am. J. Trop. Med. Hyg.55(2), 125–130 (1996).
   PubMed Web of Science ®Google Scholar
• Reiner SL, Locksley RM. The regulation of immunity to Leishmania major . Annu. Rev. Immunol.13, 151–177 (1995).
   PubMed Web of Science ®Google Scholar
• Martinez JE, Valderrama L, Gama V, Leiby DA, Saravia NG. Clonal diversity in the expression and stability of the metastatic capability of Leishmania guyanensis in the golden hamster. J. Parasitol.86(4), 792–799 (2000).
   PubMed Web of Science ®Google Scholar
• Melby PC, Tryon VV, Chandrasekar B, Freeman GL. Cloning of Syrian hamster ( Mesocricetus auratus ) cytokine cDNAs and analysis of cytokine mRNA expression in experimental visceral leishmaniasis. Infect. Immun.66(5), 2135–2142 (1998).
   PubMed Web of Science ®Google Scholar
• Amaral VF, Teva A, Porrozzi R et al.Leishmania (Leishmania) major- infected rhesus macaques (Macaca mulatta) develop varying levels of resistance against homologous re-infections. Mem. Inst. Oswaldo Cruz96(6), 795–804 (2001).
   PubMed Web of Science ®Google Scholar
• Stober CB, Lange UG, Roberts MT et al. From genome to vaccines for leishmaniasis: screening 100 novel vaccine candidates against murine Leishmania major infection. Vaccine24(14), 2602–2616 (2006).
   PubMed Web of Science ®Google Scholar
• Khamesipour A, Rafati S, Davoudi N, Maboudi F, Modabber F. Leishmaniasis vaccine candidates for development: a global overview. Indian J. Med. Res.123(3), 423–438 (2006).
   PubMed Web of Science ®Google Scholar
• Khamesipour A, Dowlati Y, Asilian A et al. Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine23(28), 3642–3648 (2005).
   PubMed Web of Science ®Google Scholar
• Tacket CO, Cohen MB, Wasserman SS et al. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with Vibrio cholerae O1 El Tor Inaba three months after vaccination. Infect. Immun.67(12), 6341–6345 (1999).
   PubMed Web of Science ®Google Scholar
• Spath GF, Epstein L, Leader B et al. Lipophosphoglycan is a virulence factor distinct from related glycoconjugates in the protozoan parasite Leishmania major . Proc.Natl Acad. Sci. USA97(16), 9258–9263 (2000).
   PubMed Web of Science ®Google Scholar
• Spath GF, Lye LF, Segawa H, Sacks DL, Turco SJ, Beverley SM. Persistence without pathology in phosphoglycan-deficient Leishmania major . Science301(5637), 1241–1243 (2003).
   PubMed Web of Science ®Google Scholar
• Uzonna JE, Spath GF, Beverley SM, Scott P. Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response. J. Immunol.172(6), 3793–3797 (2004).
   PubMed Web of Science ®Google Scholar
• Spath GF, Lye LF, Segawa H, Turco SJ, Beverley SM. Identification of a compensatory mutant (lpg2-REV) of Leishmania major able to survive as amastigotes within macrophages without LPG2-dependent glycoconjugates and its significance to virulence and immunization strategies. Infect. Immun.72(6), 3622–3627 (2004).
   PubMed Web of Science ®Google Scholar
• Ilg T, Demar M, Harbecke D. Phosphoglycan repeat-deficient Leishmania mexicana parasites remain infectious to macrophages and mice. J. Biol. Chem.276(7), 4988–4997 (2001).
   PubMed Web of Science ®Google Scholar
• Alexander J, Coombs GH, Mottram JC. Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response. J. Immunol.161(12), 6794–6801 (1998).
   PubMed Web of Science ®Google Scholar
• Titus RG, Gueiros-Filho FJ, de Freitas LA, Beverley SM. Development of a safe live Leishmania vaccine line by gene replacement. Proc. Natl Acad. Sci. USA92(22), 10267–10271 (1995).
   PubMed Web of Science ®Google Scholar
• Veras P, Brodskyn C, Balestieri F et al. A dhfr-ts Leishmania major knockout mutant cross-protects against Leishmania amazonensis . Mem. Inst. Oswaldo Cruz.94(4), 491–496 (1999).
   PubMed Web of Science ®Google Scholar
• Brodskyn C, Beverley SM, Titus RG. Virulent or avirulent (dhfr-ts-) Leishmania major elicit predominantly a type-1 cytokine response by human cells in vitro . Clin. Exp. Immunol.119(2), 299–304 (2000).
   PubMed Web of Science ®Google Scholar
• Amaral VF, Teva A, Oliveira-Neto MP et al. Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease. Mem. Inst. Oswaldo Cruz97(7), 1041–1048 (2002).
   PubMed Web of Science ®Google Scholar
• Davoudi N, Tate CA, Warburton C, Murray A, Mahboudi F, McMaster WR. Development of a recombinant Leishmania major strain sensitive to ganciclovir and 5-fluorocytosine for use as a live vaccine challenge in clinical trials. Vaccine23(9), 1170–1177 (2005).
   PubMed Web of Science ®Google Scholar
• Howard JG, Liew FY, Hale C, Nicklin S. Prophylactic immunization against experimental leishmaniasis. II. Further characterization of the protective immunity against fatal Leishmania tropica infection induced by irradiated promastigotes. J. Immunol.132(1), 450–455 (1984).
   PubMed Web of Science ®Google Scholar
• Gicheru MM, Olobo JO, Anjili CO, Orago AS, Modabber F, Scott P. Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection. Infect. Immun.69(1), 245–251 (2001).
   PubMed Web of Science ®Google Scholar
• Mayrink W, Genaro O, Silva JC et al. Phase I and II open clinical trials of a vaccine against Leishmania chagasi infections in dogs. Mem. Inst. Oswaldo Cruz91(6), 695–697 (1996).
   PubMed Web of Science ®Google Scholar
• Mohebali M, Khamesipour A, Mobedi I, Zarei Z, Hashemi-Fesharki R. Double-blind randomized efficacy field trial of alum precipitated autoclaved Leishmania major vaccine mixed with BCG against canine visceral leishmaniasis in Meshkin-Shahr district, I.R. Iran. Vaccine22(29–30), 4097–4100 (2004).
   PubMed Web of Science ®Google Scholar
• Mayrink W, Williams P, Coelho MV et al. Epidemiology of dermal leishmaniasis in the Rio Doce Valley, State of Minas Gerais, Brazil. Ann. Trop. Med. Parasitol.73(2), 123–137 (1979).
   PubMed Web of Science ®Google Scholar
• Mayrink W, da Costa CA, Magalhaes PA et al. A field trial of a vaccine against American dermal leishmaniasis. Trans. R. Soc. Trop. Med. Hyg.73(4), 385–387 (1979).
   PubMed Web of Science ®Google Scholar
• Armijos RX, Weigel MM, Calvopina M, Hidalgo A, Cevallos W, Correa J. Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis. Vaccine22(9–10), 1320–1326 (2004).
   PubMed Web of Science ®Google Scholar
• Velez ID, Gilchrist K, Arbelaez MP et al. Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia. Trans. R. Soc. Trop. Med. Hyg.99(8), 593–598 (2005).
   PubMed Web of Science ®Google Scholar
• Armijos RX, Weigel MM, Romero L, Garcia V, Salazar J. Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: how long does protection last? J. Infect Dis.187(12), 1959–1961 (2003).
   PubMed Web of Science ®Google Scholar
• Sharifi I, FeKri AR, Aflatonian MR et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet351(9115), 1540–1543 (1998).
   PubMed Web of Science ®Google Scholar
• Momeni AZ, Jalayer T, Emamjomeh M et al. A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine17(5), 466–472 (1999).
   PubMed Web of Science ®Google Scholar
• Khalil EA, El Hassan AM, Zijlstra EE et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet356(9241), 1565–1569 (2000).
   PubMed Web of Science ®Google Scholar
• Handman E, Mitchell GF. Immunization with Leishmania receptor for macrophages protects mice against cutaneous leishmaniasis. Proc. Natl Acad. Sci. USA82(17), 5910–5914 (1985).
   PubMed Web of Science ®Google Scholar
• Walker PS, Scharton-Kersten T, Rowton ED et al. Genetic immunization with glycoprotein 63 cDNA results in a helper T cell type 1 immune response and protection in a murine model of leishmaniasis. Hum. Gene Ther.9(13), 1899–1907 (1998).
   PubMed Web of Science ®Google Scholar
• Spitzer N, Jardim A, Lippert D, Olafson RW. Long-term protection of mice against Leishmania major with a synthetic peptide vaccine. Vaccine17(11–12), 1298–1300 (1999).
   PubMed Web of Science ®Google Scholar
• Russell DG, Alexander J. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes. J. Immunol.140(4), 1274–1279 (1988).
   PubMed Web of Science ®Google Scholar
• Abdelhak S, Louzir H, Timm J et al. Recombinant BCG expressing the Leishmania surface antigen Gp63 induces protective immunity against Leishmania major infection in BALB/c mice. Microbiology141(Pt 7), 1585–1592 (1995).
   PubMed Web of Science ®Google Scholar
• Connell ND, Medina-Acosta E, McMaster WR, Bloom BR, Russell DG. Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette–Guerin expressing the Leishmania surface proteinase gp63. Proc. Natl Acad. Sci. USA90(24), 11473–11477 (1993).
   PubMed Web of Science ®Google Scholar
• Yang DM, Fairweather N, Button LL, McMaster WR, Kahl LP, Liew FY. Oral Salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis. J. Immunol.145(7), 2281–2285 (1990).
   PubMed Web of Science ®Google Scholar
• Xu D, McSorley SJ, Chatfield SN, Dougan G, Liew FY. Protection against Leishmania major infection in genetically susceptible BALB/c mice by gp63 delivered orally in attenuated Salmonella typhimurium ( aroA- aroD- ). Immunology85(1), 1–7 (1995).
   PubMed Web of Science ®Google Scholar
• McSorley SJ, Xu D, Liew FY. Vaccine efficacy of Salmonella strains expressing glycoprotein 63 with different promoters. Infect. Immun.65(1), 171–178 (1997).
   PubMed Web of Science ®Google Scholar
• Gonzalez CR, Noriega FR, Huerta S et al. Immunogenicity of a Salmonella typhi CVD 908 candidate vaccine strain expressing the major surface protein gp63 of Leishmania mexicana mexicana . Vaccine16(9–10), 1043–1052 (1998).
   PubMed Web of Science ®Google Scholar
• Handman E, Button LL, McMaster RW. Leishmania major : production of recombinant gp63, its antigenicity and immunogenicity in mice. Exp. Parasitol.70(4), 427–435 (1990).
   PubMed Web of Science ®Google Scholar
• Xu D, Liew FY. Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of L. major . Immunology84(2), 173–176 (1995).
   PubMed Web of Science ®Google Scholar
• Dumonteil E, Maria Jesus RS, Javier EO, Maria del Rosario GM. DNA vaccines induce partial protection against Leishmania mexicana . Vaccine21(17–18), 2161–2168 (2003).
   PubMed Web of Science ®Google Scholar
• Dumonteil E, Andrade-Narvarez F, Escobedo-Ortegon J et al. Comparative study of DNA vaccines encoding various antigens against Leishmania mexicana . Dev. Biol. (Basel)104, 135–141 (2000).
   PubMedGoogle Scholar
• Ahmed SB, Bahloul C, Robbana C, Askri S, Dellagi K. A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to L. major . Vaccine22(13–14), 1631–1639 (2004).
   PubMed Web of Science ®Google Scholar
• Launois P, Maillard I, Pingel S et al. IL-4 rapidly produced by V β 4 V α 8 CD4+ T cells instructs Th2 development and susceptibility to Leishmania major in BALB/c mice. Immunity6(5), 541–549 (1997).
   PubMed Web of Science ®Google Scholar
• Julia V, Glaichenhaus N. CD4+ T cells which react to the Leishmania major LACK antigen rapidly secrete interleukin-4 and are detrimental to the host in resistant B10.D2 mice. Infect. Immun.67(7), 3641–3644 (1999).
   PubMed Web of Science ®Google Scholar
• Mougneau E, Altare F, Wakil AE et al. Expression cloning of a protective Leishmania antigen. Science268(5210), 563–566 (1995).
   PubMed Web of Science ®Google Scholar
• Gurunathan S, Sacks DL, Brown DR et al. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major . J. Exp. Med.186(7), 1137–1147 (1997).
   PubMed Web of Science ®Google Scholar
• Soussi N, Milon G, Colle JH, Mougneau E, Glaichenhaus N, Goossens PL. Listeria monocytogenes as a short-lived delivery system for the induction of type 1 cell-mediated immunity against the p36/LACK antigen of Leishmania major . Infect. Immun.68(3), 1498–1506 (2000).
   PubMed Web of Science ®Google Scholar
• Salay G, Dorta ML, Santos NM et al. Testing of four Leishmania vaccine candidates in a mouse model of infection with Leishmania (Viannia) braziliensis , the main causative agent of cutaneous leishmaniasis in the New World. Clin. Vaccine Immunol.14(9), 1173–1181 (2007).
   PubMedGoogle Scholar
• Melby PC, Yang J, Zhao W, Perez LE, Cheng J. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect. Immun.69(8), 4719–4725 (2001).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Cortes A, Ojeda A, Lopez-Fuertes L et al. Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge. Vaccine25(46), 7962–7971 (2007).
   PubMed Web of Science ®Google Scholar
• Marques-da-Silva EA, Coelho EA, Gomes DC et al. Intramuscular immunization with p36(LACK) DNA vaccine induces IFN-γ production but does not protect BALB/c mice against Leishmania chagasi intravenous challenge. Parasitol. Res.98(1), 67–74 (2005).
   PubMed Web of Science ®Google Scholar
• Gonzalo RM, del Real G, Rodriguez JR et al. A heterologous prime–boost regime using DNA and recombinant vaccinia virus expressing the Leishmania infantum p36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis. Vaccine20(7–8), 1226–1231 (2002).
   PubMed Web of Science ®Google Scholar
• Tapia E, Perez-Jimenez E, Lopez-Fuertes L, Gonzalo R, Gherardi MM, Esteban M. The combination of DNA vectors expressing IL-12 + IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36/LACK. Microbes Infect.5(2), 73–84 (2003).
   PubMed Web of Science ®Google Scholar
• Lange UG, Mastroeni P, Blackwell JM, Stober CB. DNA– Salmonella enterica serovar Typhimurium primer–booster vaccination biases towards T helper 1 responses and enhances protection against Leishmania major infection in mice. Infect. Immun.72(8), 4924–4928 (2004).
   PubMed Web of Science ®Google Scholar
• Ramiro MJ, Zarate JJ, Hanke T et al. Protection in dogs against visceral leishmaniasis caused by Leishmania infantum is achieved by immunization with a heterologous prime–boost regime using DNA and vaccinia recombinant vectors expressing LACK. Vaccine21(19–20), 2474–2484 (2003).
   PubMed Web of Science ®Google Scholar
• Lopez-Fuertes L, Perez-Jimenez E, Vila-Coro AJ et al. DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice. Vaccine21(3–4), 247–257 (2002).
   PubMed Web of Science ®Google Scholar
• Pinto EF, Pinheiro RO, Rayol A, Larraga V, Rossi-Bergmann B. Intranasal vaccination against cutaneous leishmaniasis with a particulated leishmanial antigen or DNA encoding LACK. Infect. Immun.72(8), 4521–4527 (2004).
   PubMed Web of Science ®Google Scholar
• Gomes DC, Pinto EF, de Melo LD et al. Intranasal delivery of naked DNA encoding the LACK antigen leads to protective immunity against visceral leishmaniasis in mice. Vaccine25(12), 2168–2172 (2007).
   PubMed Web of Science ®Google Scholar
• Rafati S, Kariminia A, Seyde-Eslami S, Narimani M, Taheri T, Lebbatard M. Recombinant cysteine proteinases-based vaccines against Leishmania major in BALB/c mice: the partial protection relies on interferon γ producing CD8+ T lymphocyte activation. Vaccine20(19–20), 2439–2447 (2002).
   PubMed Web of Science ®Google Scholar
• Zadeh-Vakili A, Taheri T, Taslimi Y, Doustdari F, Salmanian AH, Rafati S. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases type I (CPB) and type II (CPA), partially protects against leishmaniasis. Vaccine22(15–16), 1930–1940 (2004).
   PubMed Web of Science ®Google Scholar
• Rafati S, Salmanian AH, Taheri T, Vafa M, Fasel N. A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major . Vaccine19(25–26), 3369–3375 (2001).
   PubMed Web of Science ®Google Scholar
• Rafati S, Nakhaee A, Taheri T et al. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum . Vaccine23(28), 3716–3725 (2005).
   PubMed Web of Science ®Google Scholar
• Rafati S, Zahedifard F, Nazgouee F. Prime–boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine24(12), 2169–2175 (2006).
   PubMed Web of Science ®Google Scholar
• Rafati S, Zahedifard F, Azari MK, Taslimi Y, Taheri T. Leishmania infantum : prime boost vaccination with C-terminal extension of cysteine proteinase type I displays both type 1 and 2 immune signatures in BALB/c mice. Exp. Parasitol.118(3), 393–401 (2008).
   PubMed Web of Science ®Google Scholar
• Handman E, Symons FM, Baldwin TM, Curtis JM, Scheerlinck JP. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a Th1 type of immune response. Infect. Immun.63(11), 4261–4267 (1995).
   PubMed Web of Science ®Google Scholar
• Sjolander A, Baldwin TM, Curtis JM, Bengtsson KL, Handman E. Vaccination with recombinant parasite surface antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection. Vaccine16(20), 2077–2084 (1998).
   PubMed Web of Science ®Google Scholar
• McMahon-Pratt D, Rodriguez D, Rodriguez JR et al. Recombinant vaccinia viruses expressing GP46/M-2 protect against Leishmania infection. Infect. Immun.61(8), 3351–3359 (1993).
   PubMed Web of Science ®Google Scholar
• Handman E, Noormohammadi AH, Curtis JM, Baldwin T, Sjolander A. Therapy of murine cutaneous leishmaniasis by DNA vaccination. Vaccine18(26), 3011–3017 (2000).
   PubMed Web of Science ®Google Scholar
• de Carvalho LP, Soto M, Jeronimo S et al. Characterization of the immune response to Leishmania infantum recombinant antigens. Microbes Infect.5(1), 7–12 (2003).
   PubMed Web of Science ®Google Scholar
• Basu R, Bhaumik S, Basu JM, Naskar K, De T, Roy S. Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J. Immunol.174(11), 7160–7171 (2005).
   PubMed Web of Science ®Google Scholar
• Solioz N, Blum-Tirouvanziam U, Jacquet R et al. The protective capacities of histone H1 against experimental murine cutaneous leishmaniasis. Vaccine18(9–10), 850–859 (1999).
   PubMed Web of Science ®Google Scholar
• Chenik M, Louzir H, Ksontini H, Dilou A, Abdmouleh I, Dellagi K. Vaccination with the divergent portion of the protein histone H2B of Leishmania protects susceptible BALB/c mice against a virulent challenge with Leishmania major . Vaccine24(14), 2521–2529 (2006).
   PubMed Web of Science ®Google Scholar
• Carrion J, Folgueira C, Alonso C. Transitory or long-lasting immunity to Leishmania major infection: the result of immunogenicity and multicomponent properties of histone DNA vaccines. Vaccine26(9), 1155–1165 (2008).
   PubMed Web of Science ®Google Scholar
• Iborra S, Soto M, Carrion J, Alonso C, Requena JM. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis. Vaccine22(29–30), 3865–3876 (2004).
   PubMed Web of Science ®Google Scholar
• Soto M, Requena JM, Quijada L et al. During active viscerocutaneous leishmaniasis the anti-P2 humoral response is specifically triggered by the parasite P proteins. Clin. Exp. Immunol.100(2), 246–252 (1995).
   PubMed Web of Science ®Google Scholar
• Soto M, Requena JM, Quijada L, Guzman F, Patarroyo ME, Alonso C. Identification of the Leishmania infantum P0 ribosomal protein epitope in canine visceral leishmaniasis. Immunol. Lett.48(1), 23–28 (1995).
   PubMed Web of Science ®Google Scholar
• Iborra S, Soto M, Carrion J et al. The Leishmania infantum acidic ribosomal protein P0 administered as a DNA vaccine confers protective immunity to Leishmania major infection in BALB/c mice. Infect. Immun.71(11), 6562–6572 (2003).
   PubMed Web of Science ®Google Scholar
• Iborra S, Carrion J, Anderson C, Alonso C, Sacks D, Soto M. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice. Infect. Immun.73(9), 5842–5852 (2005).
   PubMed Web of Science ®Google Scholar
• Iborra S, Abanades DR, Parody N et al. The immunodominant T helper 2 (Th2) response elicited in BALB/c mice by the Leishmania LiP2a and LiP2b acidic ribosomal proteins cannot be reverted by strong Th1 inducers. Clin. Exp. Immunol.150(2), 375–385 (2007).
   PubMed Web of Science ®Google Scholar
• Coler RN, Reed SG. Second-generation vaccines against leishmaniasis. Trends Parasitol.21(5), 244–249 (2005).
   PubMed Web of Science ®Google Scholar
• Campos-Neto A, Porrozzi R, Greeson K et al. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect. Immun.69(6), 4103–4108 (2001).
   PubMed Web of Science ®Google Scholar
• Campos-Neto A, Webb JR, Greeson K, Coler RN, Skeiky YA, Reed SG. Vaccination with plasmid DNA encoding TSA/LmSTI1 leishmanial fusion proteins confers protection against Leishmania major infection in susceptible BALB/c mice. Infect. Immun.70(6), 2828–2836 (2002).
   PubMed Web of Science ®Google Scholar
• Skeiky YA, Kennedy M, Kaufman D et al. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile. J. Immunol.161(11), 6171–6179 (1998).
   PubMed Web of Science ®Google Scholar
• Probst P, Skeiky YA, Steeves M, Gervassi A, Grabstein KH, Reed SG. A Leishmania protein that modulates interleukin (IL)-12, IL-10 and tumor necrosis factor-α production and expression of B7-1 in human monocyte-derived antigen-presenting cells. Eur. J. Immunol.27(10), 2634–2642 (1997).
   PubMed Web of Science ®Google Scholar
• Coler RN, Skeiky YA, Bernards K et al. Immunization with a polyprotein vaccine consisting of the T-cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis. Infect. Immun.70(8), 4215–4225 (2002).
   PubMed Web of Science ®Google Scholar
• Skeiky YA, Coler RN, Brannon M et al. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant. Vaccine20(27–28), 3292–3303 (2002).
   PubMed Web of Science ®Google Scholar
• Coler RN, Goto Y, Bogatzki L, Raman V, Reed SG. Leish-111f, a recombinant polyprotein vaccine that protects against visceral leishmaniasis by elicitation of CD4+ T cells. Infect. Immun.75(9), 4648–4654 (2007).
   PubMed Web of Science ®Google Scholar
• Fujiwara RT, Vale AM, Franca da Silva JC et al. Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis. Vet. Res.36(5–6), 827–838 (2005).
   PubMed Web of Science ®Google Scholar
• Gradoni L, Foglia Manzillo V, Pagano A et al. Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals. Vaccine23(45), 5245–5251 (2005).
   PubMed Web of Science ®Google Scholar
• Badaro R, Lobo I, Munos A et al. Immunotherapy for drug-refractory mucosal leishmaniasis. J. Infect. Dis.194(8), 1151–1159 (2006).
   PubMed Web of Science ®Google Scholar
• Flohe SB, Bauer C, Flohe S, Moll H. Antigen-pulsed epidermal Langerhans cells protect susceptible mice from infection with the intracellular parasite Leishmania major . Eur. J. Immunol.28(11), 3800–3811 (1998).
   PubMed Web of Science ®Google Scholar
• von Stebut E, Belkaid Y, Jakob T, Sacks DL, Udey MC. Uptake of Leishmania major amastigotes results in activation and interleukin 12 release from murine skin-derived dendritic cells: implications for the initiation of anti- Leishmania immunity. J. Exp. Med.188(8), 1547–1552 (1998).
   PubMed Web of Science ®Google Scholar
• Ahuja SS, Reddick RL, Sato N et al. Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection. J. Immunol.163(7), 3890–3897 (1999).
   PubMed Web of Science ®Google Scholar
• Berberich C, Ramirez-Pineda JR, Hambrecht C, Alber G, Skeiky YA, Moll H. Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be induced by molecularly defined antigens. J. Immunol.170(6), 3171–3179 (2003).
   PubMed Web of Science ®Google Scholar
• Tsagozis P, Karagouni E, Dotsika E. Dendritic cells pulsed with peptides of gp63 induce differential protection against experimental cutaneous leishmaniasis. Int. J. Immunopathol. Pharmacol.17(3), 343–352 (2004).
   PubMed Web of Science ®Google Scholar
• Carrion J, Folgueira C, Alonso C. Immunization strategies against visceral leishmaniosis with the nucleosomal histones of Leishmania infantum encoded in DNA vaccine or pulsed in dendritic cells. Vaccine26(20), 2537–2544 (2008).
   PubMed Web of Science ®Google Scholar
• Titus RG, Ribeiro JM. Salivary gland lysates from the sand fly Lutzomyia longipalpis enhance Leishmania infectivity. Science239(4845), 1306–1308 (1988).
   PubMed Web of Science ®Google Scholar
• Kamhawi S, Belkaid Y, Modi G, Rowton E, Sacks D. Protection against cutaneous leishmaniasis resulting from bites of uninfected sand flies. Science290(5495), 1351–1354 (2000).
   PubMed Web of Science ®Google Scholar
• de Moura TR, Oliveira F, Novais FO et al. Enhanced Leishmania braziliensis infection following pre-exposure to sandfly saliva. PLoS Negl. Trop. Dis.1(2), e84 (2007).
   PubMedGoogle Scholar
• Morris RV, Shoemaker CB, David JR, Lanzaro GC, Titus RG. Sandfly maxadilan exacerbates infection with Leishmania major and vaccinating against it protects against L. major infection. J. Immunol.167(9), 5226–5230 (2001).
   PubMed Web of Science ®Google Scholar
• Valenzuela JG, Belkaid Y, Garfield MK et al. Toward a defined anti- Leishmania vaccine targeting vector antigens: characterization of a protective salivary protein. J. Exp. Med.194(3), 331–342 (2001).
   PubMed Web of Science ®Google Scholar